本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

Veru Inc.

3.42
-0.2600-7.07%
成交量:10.95萬
成交額:38.80萬
市值:5,010.43萬
市盈率:-1.38
高:3.66
開:3.66
低:3.41
收:3.68
52周最高:14.20
52周最低:2.64
股本:1,465.04萬
流通股本:1,257.83萬
量比:0.67
換手率:0.87%
股息:- -
股息率:- -
每股收益(TTM):-2.4829
每股收益(LYR):-2.8027
淨資產收益率:-106.02%
總資產收益率:-52.13%
市淨率:3.27
市盈率(LYR):-1.22

資料載入中...

公司資料

公司名字:
Veru Inc.
交易所:
NASDAQ
成立時間:
1971
員工人數:
210
公司地址:
2916 North Miami Avenue,Suite 1000,Miami,Florida,United States
郵編:
33127
電話:
傳真:
- -
簡介:
Veru Inc.成立於1971年。是一家臨床後期生物製藥公司,專註於開發治療代謝性疾病、腫瘤學、ARDS的新藥。該公司的藥物開發計劃包括兩個晚期新化學實體,enobosarm和sabizabulin。

董事

名稱
職位
Harry Fisch
Director,Vice Chairman of the Board,Chief Corporate Officer
Mitchell S. Steiner
President and Chief Executive Officer and Director,Chairman of the Board
Grace Hyun
Director
Lucy Lu
Director
Mario Eisenberger
Director
Michael L. Rankowitz
Director

股東

名稱
職位
Mitchell S. Steiner
President and Chief Executive Officer and Director,Chairman of the Board
Michele Greco
Chief Financial Officer and Chief Administrative Officer
Harry Fisch
Director,Vice Chairman of the Board,Chief Corporate Officer
K. Gary Barnette
Chief Scientific Officer